CDK4/6i target the cell cycle with a bone marrow suppression effect as the primary dose-limiting toxicity; the occurrence of neutropenia is rather a rule—in our study 79% of patients experienced at least one episode, consistent with meta-analysis that reported all-grade neutropenia frequency of up to 80% [17]. This evidence concerns the gene CDK4 and neutropenia.